Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial. - Hecht JR; Park YS; Tabernero J; Lee MA; Lee S; Virgili AC; Van den Eynde M; Fontana E; Fakih M; Asghari G; So J; Stein A; et al. (Lancet (London, England), 2025)